gdc
PSSGuide_2021
Kidney Cancer

Drugs for Kidney Cancer (Renal-Cell Carcinoma)

Find financial assistance programs available for kidney cancer drugs.

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and co-insurance for Afinitor. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Afinitor for free until a prescription drug coverage becomes available to them.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with interferon-alfa, for the treatment of patients with metastatic renal-cell carcinoma (kidney cancer).

Genentech Oncology offers 2 financial assistance programs for patients using Avastin:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Bavencio (avelumab)

Drug company: EMD Serono
844-826-8371

Bavencio is a PD-L1 inhibitor used, in combination with axitinib, for the first-line treatment of patients with advanced renal-cell carcinoma (kidney cancer).

EMD Serono offers 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $10 copay for Bavencio at participating medical facilities and pharmacies and may be eligible for copay assistance up to a maximum of $30,000 annually.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Cabometyx (cabozantinib) Tablets

Drug company: Exelixis
844-900-3273

Cabometyx is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer). Cabometyx is also used, in combination with Opdivo, for the first-line treatment of patients with advanced renalcell carcinoma.

Exelixis Access Services offers 2 financial assistance programs for patients using Cabometyx:

EASE Co-pay Program

Patients with private insurance who are eligible for this program will pay $0 per month for Cabometyx, for a maximum benefit of $25,000 per year.

EASE Patient Assistance Program

This program provides Cabometyx free of charge to qualifying patients who are uninsured or underinsured.

Fotivda (tivozanib) Capsules

Drug company: AVEO Pharmaceuticals
833-368-4832

Fotivda is a tyrosine kinase inhibitor used for the treatment of adults with relapsed or refractory advanced renal-cell carcinoma (kidney cancer) after 2 or more previous therapies.

AVEO ACE offers 2 financial assistance programs for patients using Fotivda:

AVEO ACE Co-pay Assistance Program

Eligible patients who have private insurance may pay as little as $0 for Fotivda, with a maximum annual benefit of $40,000.

AVEO ACE Patient Assistance Program

Uninsured or underinsured patients, who meet certain income and financial requirements, may receive Fotivda at no cost.

Inlyta (axitinib)

Drug company: Pfizer
877-744-5675

Inlyta is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Pfizer Oncology Together offers 2 financial assistance programs for patients using Inlyta:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Inlyta is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Inlyta for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Inlyta for free.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used, in combination with axitinib, for the first-line treatment of patients with advanced renal-cell carcinoma (kidney cancer). Keytruda is also used, in combination with Lenvima, for the first-line treatment of adults with advanced renal-cell carcinoma. In addition, Keytruda is used alone for the adjuvant (additional) treatment of patients with renal-cell carcinoma that is at intermediate-high or high risk of recurrence (coming back) after nephrectomy, or after nephrectomy and resection of metastatic lesions.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-Pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive free Keytruda. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for a couple, or $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lenvima (lenvatinib) Capsules

Drug company: Eisai
866-613-4724

Lenvima is a kinase inhibitor used, in combination with everolimus, for the treatment of patients with advanced renal-cell carcinoma (kidney cancer). Lenvima is also used, in combination with Keytruda, for the first-line treatment of adults with advanced renal-cell carcinoma.

Eisai offers 2 financial assistance programs for patients using Lenvima:

Lenvima $0 Co-Pay Program

Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.

Eisai Assistance Program

This program provides Lenvima at no cost to patients with financial needs who meet the program’s eligibility criteria.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with interferon-alfa, for the treatment of patients with metastatic renal-cell carcinoma (kidney cancer).

Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements may receive Mvasi for free.

Nexavar (sorafenib) Tablets

Drug company: Bayer
866-639-2827

Nexavar is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Bayer offers 2 financial assistance programs for patients using Nexavar:

Nexavar $0 Co-Pay Program

With this program, patients with private insurance pay $0 copay for Nexavar, and the program pays up to $25,000 annually, with no monthly maximum.

Bayer US Patient Assistance Foundation

This foundation provides free medicine for patients who are prescribed a Bayer medication and are uninsured or underinsured and meet certain eligibility criteria.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer). Opdivo is also used, in combination with Yervoy, for the treatment of patients with intermediate- or poor-risk advanced renal-cell carcinoma that was not previously treated; and in combination with Cabometyx, for the first-line treatment of patients with advanced renal-cell carcinoma.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Sutent (sunitinib malate) Capsules

Drug company: Pfizer
877-744-5675

Sutent is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Pfizer Oncology Together offers 2 financial assistance programs for patients using Sutent:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Sutent is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Sutent for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Sutent for free.

Torisel (temsirolimus)

Drug company: Pfizer
877-744-5675

Torisel is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Pfizer Oncology Together offers 1 financial assistance program for patients using Torisel:

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Torisel for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Torisel for free.

Votrient (pazopanib)

Drug company: Novartis
800-245-5356

Votrient is a kinase inhibitor used for the treatment of patients with advanced renal-cell carcinoma (kidney cancer).

Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Votrient:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and co-insurance for Votrient. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Votrient for free until a prescription drug coverage becomes available to them.

Welireg (belzutifan) Tablets

Drug company: Merck
855-257-3932

Welireg is a hypoxia-inducible factor inhibitor used for the treatment of adults with von Hippel-Lindau disease and renal cell-carcinoma (kidney cancer) that is not requiring surgery.

Merck Access Program offers 2 financial assistance programs for patients using Welireg:

Merck Co-Pay Coupon

Eligible patients who have private insurance may pay as little as $5 for the first out-of-pocket cost of Welireg, with a maximum program savings of up to $8,700 per patient. Coupon is valid for up to 90-day supply per prescription fill and may be redeemed only once every 21 days.

Merck Patient Assistance Program

Uninsured or underinsured patients may receive Welireg for free through this program. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for couples, or $132,000 or less for a family of 4.

Yervoy (ipilimumab)

Drug company: Bristol Myers Squibb
800-861-0048

Yervoy is a human CTLA-4 inhibitor used, in combination with Opdivo, for the treatment of patients with intermediate- or poor-risk advanced renal-cell carcinoma (kidney cancer) that was not previously treated.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Yervoy:

BMS Oncology Co-pay Assistance Program

This program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per product (or $50,000 annually for 2 BMS drugs administered in combination).

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Yervoy may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Zirabev (bevacizumab-bvzr)

Drug company: Pfizer
877-744-5675

Zirabev, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with interferon-alfa, for the treatment of patients with metastatic renal-cell carcinoma (kidney cancer).

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Zirabev:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Zirabev is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Zirabev for free or at a savings. Eligible patients with government insurance may also receive Zirabev for free if they cannot find independent charitable foundation support.

Table. Drugs Prescribed for Kidney (Renal-Cell) Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services



    Drug name (generic name)
  • Cabometyx (cabozantinib) Tablets
  • Drug company
  • Exelixis
  • Indication
  • Treatment of advanced renal-cell carcinoma

    First-line treatment, in combination with Opdivo, of patients with advanced renal-cell carcinoma
  • Patient support services
  • EASE Co-pay Program
    844-900-3273

    EASE Patient Assistance Program
    844-900-3273



    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • First-line treatment of advanced renalcell carcinoma, in combination with axitinib

    First-line treatment, in combination with Lenvima, of adults with advanced renal-cell carcinoma

    Adjuvant (additional) treatment of patients with renal-cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions
  • Patient support services
  • Merck Co-Pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Lenvima (lenvatinib) Capsules
  • Drug company
  • Eisai
  • Indication
  • Treatment of advanced renal-cell carcinoma

    First-line treatment, in combination with Keytruda, of adults with advanced renal-cell carcinoma
  • Patient support services
  • Lenvima $0 Co-Pay Program
    800-727-5400

    Eisai Assistance Program
    800-727-5400

    Drug name (generic name)
  • Mvasi (bevacizumabawwb)
  • Drug company
  • Amgen
  • Indication
  • Treatment of metastatic renal-cell carcinoma, in combination with interferon-alfa
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436


    Drug name (generic name)
  • Opdivo (nivolumab)
  • Drug company
  • Bristol Myers Squibb
  • Indication
  • Treatment of advanced renal-cell carcinoma

    Untreated, intermediate or poor-risk advanced renal-cell carcinoma, in combination with Yervoy

    First-line treatment, in combination with Cabometyx, of patients with advanced renal-cell carcinoma
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003


    Drug name (generic name)
  • Torisel (temsirolimus)
  • Drug company
  • Pfizer
  • Indication
  • Treatment of advanced renal-cell carcinoma
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675


    Drug name (generic name)
  • Welireg (belzutifan) Tablets
  • Drug company
  • Merck
  • Indication
  • Treatment of adults with von Hippel-Lindau disease and renal-cell carcinoma not requiring surgery
  • Patient support services
  • Merck Co-Pay Coupon
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932



Share this:

Last modified: March 21, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest